The discovery of new therapeutic targets and the personalization of treatments are two active areas of cancer research. New studies suggest that a 'co-clinical' approach may expedite both therapeutic target validation and risk stratification in patients with advanced prostate cancer.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
Prices may be subject to local taxes which are calculated during checkout
Lunardi, A. et al. Nat. Genet. 45, 747–755 (2013).
Nardella, C., Lunardi, A., Patnaik, A., Cantley, L.C. & Pandolfi, P.P. Cancer Discov. 1, 108–116 (2011).
Ryan, C.J. & Tindall, D.J. J. Clin. Oncol. 29, 3651–3658 (2011).
Grasso, C.S. et al. Nature 487, 239–243 (2012).
Barbieri, C.E. et al. Nat. Genet. 44, 685–689 (2012).
Wang, S. et al. Cancer Cell 4, 209–221 (2003).
Gao, H., Ouyang, X., Banach-Petrosky, W.A., Shen, M.M. & Abate-Shen, C. Cancer Res. 66, 7929–7933 (2006).
Wang, G. et al. Nat. Genet. 45, 739–746 (2013).
Kumari, R. et al. Carcinogenesis 33, 2076–2083 (2012).
Beroukhim, R. et al. Nature 463, 899–905 (2010).
Tomlins, S.A. et al. Science 310, 644–648 (2005).
Chen, C.D. et al. Nat. Med. 10, 33–39 (2004).
Sun, Y. et al. Nat. Med. 18, 1359–1368 (2012).
Straussman, R. et al. Nature 487, 500–504 (2012).
Shah, S.K. et al. J. Urol. 181, 621–626 (2009).
The authors declare no competing financial interests.
About this article
Cite this article
Zhao, S., Nelson, P. Leveraging the species barrier to advance cancer therapy. Nat Genet 45, 718–720 (2013). https://doi.org/10.1038/ng.2683